Coeliac disease,
vitiligo, and
alopecia areata are all autoimmune conditions, meaning the immune system mistakenly attacks the body's own cells and tissues. Together they affect hundreds of thousands of Australians, yet effective long-term treatments remain limited for many people living with these conditions.
This study is evaluating a new investigational antibody that may one day help treat all three conditions. Before it can progress to patient trials, researchers need to understand how healthy adults process and respond to it under closely monitored conditions.
By taking part as a healthy volunteer for an antibody research study, you are contributing to scientific development that could meaningfully improve the lives of people living with these conditions.
This study does not require a diagnosis of coeliac disease, vitiligo, or alopecia areata. It is open to healthy adults aged 18–60 who meet the eligibility criteria and are comfortable with a monitored clinic stay at our Morayfield clinic in Moreton Bay and the Maroochy Private Hospital clinic in Maroochydore.
Important update:
We paused enrollment at our Morayfield clinic. New dates will be announced soon. The investigational antibody is administered on Day 1 either by injection under the skin or by intravenous (IV) infusion, depending on cohort assignment. This is a randomised, double-blind, placebo-controlled antibody research study with a 3:1 ratio, meaning three out of four participants receive the investigational medicine, and one out of four receives a placebo.
Neither participants nor study staff know the assignment.
Group A participants complete a 5-night confinement period, followed by 3-month follow-up visits for our Morayfield and Maroochydore clinics.
Group B participants complete four confinement periods: 5 consecutive days followed by 16 days, plus a follow-up period lasting 3.5 months. Participants in this group will only take part in the Morayfield clinic.
All procedures will be explained clearly, and participants can ask questions at any time.
